Zenas BioPharma reports successful Phase 3 trial: Obexelimab reduces IgG4-RD flare risk by 56%.
Obexelimab successfully achieved its primary objective by showing a substantial and statistically significant 56% decrease in the risk of IgG4-RD flare.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments